DAFTAR PUSTAKA

Almond l Clemens l, Engel's H, Halstead S., Khiem HR, Pabloz-Mendez A, etal. 2002. Accelerating the development and introduction of dengue vaccinefool' poor children, 5-8 December 2001, Ho Chi Minh City, VietNam.Vaccine, 20: p. 3043-3046.

Amin P., Bhandare S., and Srivastava A 2001. Dengue, Dengue HaemorrhagicFever, Dengue Shock Syndrome.http://www.bl1i.orQ.!journal/200I 4303 iulvOlircvicw 380.11t11127-04-2004.

Anderson R, Wang S., Osiowy C. and Issekutz AC. 1997. Activation ofEndothelial Cells via Antibody-enhanced Dengue Virus infection ofPeripheral Blood Monocytes. 1. Virol., 71 (6): p. 4226-4232.

Anna Durbin, Phase Ihttp://c linicaltrials. gOY!ct{Q.ui!infilipharu~ssjonid=269

3] 9642BSC64CBEB

7BFAB09B4BB133, 9 ok'1ober2004).

Bancroft W.R., Top, Jr F.R., Eckels K.H, Anderson, Jr. lH, McCown lM., andRussell P.K. 1981. Dengue-2 vaccine: virological, immunological, andclinical responses of six yellow fever-immune recipients. l1?fect Immlln., 31(2): p. 698-703.

Bhamarapravati N. and Y oksan S. 1997. Live attenuated tetravalent denguevaccine. In DJ. Gubler and G. Kune: Dengue and Dengue HemorrhagicFever. Cambridge: University press. p. 367-377.

. 2000. Live attenuated tetravalent dengue vaccine. Vaccine, 18 (2): p.44-47.

Blaney lE. Jr, Manipon G.G., Firestone c.Y, Johnson D.H, Hanson c.T.,Murphy RR, et al. 2003. Mutations which enhance the replication ofdengue virus type 4 and an antigenic chimeric dengue virus type 2/4 vaccinecandidate in Vero cells. Vaccine, 21 (27-30): p. 4317-27.

Blaney Jr lE., Johnson D.H, Firestone c.Y, Hanson C.T., Murphy B.R, andWhitehead S.S. 2001. Chemical Mutagenesis of Dengue Virus Type4 Yields Mutant Viruses Which Are Temperature Sensitive in Vero Cells orHuman Liver Cells and Attenuated in Mice. Journal of Virology, 75 (20): p.9731-40.

Bosch I., Xhaja K., Estevez L., Raines G., Melichar H, Warke RY., et al. 2002.Increased Production of Interleukin-8 in Primary Human Monocytes and in

134

135

Human Epithelial and Endothelial Cell Lines after Dengue Virus Challenge.Journal of Virology, 76 (11): p. 5588-5597.

Bosch 1. 2003. Gene Expression of Host Cells Infected with Dengue Virus.http://\yww.ipk .sId.cui curSO-Q~l}gUC-memoria s/confcrcncias- roam stralc s/23. pdf,28-01-2005.

Bray M., Men R., and Lai C.I. 1996. Monkeys immunized with intertypicchimeric dengue viruses are protected against wild-type virus challenge. JVirol., 70 (6): p. 4162-4166.

Bumi c., Rantam F.A, Soegijanto S., dan Hamid 1.S. 2004. Determinan virulensivirus dengue. In Soegeng Soegijanto: Demam berdarah dengue: tiryauanOOn temuan bam di era 2003. Surabaya: Airlangga University Press. p. 91-97.

Catteau A, Roue G., Yuste V.I., Susin S.A, and Despres P. 2003. Expression ofdengue ApoptoM sequence results in disruption of mitochondrial potentialand caspase activation. Biochimie, 85 (8): pp. 789-793.

CDS.1999. Regional guidenesson Dengue/DHF prevention and control.http://ww\v.org/whosea/cds!index.htl11 , 13-] 0-2004.

Cella M., Salio M., Sakakibara Y, Langen R., Julkllnen 1., and Lanzavecchia A1999. Maturation, activation, and protection of dendritic cells induced bydouble stranded RNA J Exp. Med, 189 (5): p. 821-829.

Chambers T.I., Liang Y, Droll D.A, Schlesinger J.J, Davidson AD., Wright PJ.,et al. 2003. Yellow Fever Virus/Dengue-2 Virus and Yellow FeverVirus/Dengue-4 Virus Chimeras: Biological Characterization,Immunogenicity, and Protection against Dengue Encephalitis in the MouseModel. Journal of Virology, 77 (6): p. 3655-3668.

Chang D.M. and Shaio M.F.1994. Production of interleukin-l (lL-l) and lL-linhibitor by human monocytes exposed to dengue virus. Journal ofInfectious Diseases, 170 (4): pp. 811-817.

Chang G.J. 1997. Molecular biology of dengue viruses. In DJ. Gubler and G.Kune: Dengue and Dengue Hemorrhagic Fever. Cambridge: Universitypress. p. 175-198.

Chang G.I., Kuno G., Purdy D.E., and Davis B.S. 2004. Recent advancement inflavivirus vaccine development. Expert Rev 'Vaccines., 3 (2): p. 199-220.

Chang HH., Shyu H.F., Wang YM., Sun D.S., Shyu RH, Tang S.S., et al. 2002.Facilitation of cell adhesion by immobilized dengue viral non structural

136

protein 1 (NS1): Arginine-glycine-aspartic acid structural mimicry withinthe dengue viral NS 1 antigen. Journal of ltifectious Diseases, ]86 (6): pp.743-751.

Chao D.Y, Lin T.H., Hwang KP., Huang J.H., Liu c.c., and King C.C.1998.dengue hemoIThagic fever epidemic in Taiwan.L/'iDV\\'..~d_~£QyincidO(EEfJ)Iy_ol1 Ono3/0_~::(L'J_~htm, 27-04-2004.

Chaturvedi u.c., Elbishbishi E.A, Agarwal R, and Mustafa AS. 2001. Cytotoxicfactor-autoantibodies: possible role in the pathogenesis of denguehaemorrhagic fever FEMS. Immunology & Medical Microbiology, 30 (3):pp. 181-186.

Chen yc. and Wang S.Y 2002. Activation of Terminally Differentiated HumanMonocytes/Macrophages by Dengue Virus: Productive Infection,Hierarchical Production of Innate Cytokines and Chemokines, and theSynergistic Effect of Lipopolysaccharide. Journal of Virology, 76 (19): p.9877-9887.

Chen YP., Maguire T., Hileman RE., Fromm J.R, Esko J.D., Linhardt RJ. et a1.1997. Dengue virus infectivity depends on envelope protein binding to targetcel1 heparan sulfate. Nature Medicine, 3 (8): p. 866-871.

Chung N.P.Y, Chen Y, Chan V.S.F., TAM P.KH., and Lin c.L.S. 2004.Dendritic cells: sentinels against pathogens. Histology and Histopathology,]9 (1): p. 317-314.

Chungue E., Poli L., Roche c., Gestas P., Glaziou P., and Markoff LJ. 1994.Correlation between detection of plasminogen cross-reactive antibodies andhemorrhage in dengue virus infection. J l1ifect Dis., 170 (5): p. ] 304-7.

Craig S., Myat Thu H., Lowry K, Wang x.F., Holmes E.C., and Aaskov J. 2003.Diverse dengue type 2 virus population contain recombinant and bothparental viruses in a single mosqiuto host. Journal of T'irology, 77 (7): p.4463-4467.

Diamond M.S., Edgil D., Roberts T.G., Lu B., and Harris E. 2000. Infection ofHuman Cel1s by Dengue Virus Is Modulated by Different Cel1 Types andViral Strains. Journal ofTTirology, 74 (17): p. 7814-7823.

Dos Santos F.B., Miagostovich M.P., Noguiera M.R, Schatmayr H.G., RileyL.W., Harris E. Analysis of recombinant Dengue virus polypeptides forDengue diagnosis ang evaluation of the humoral immune response. Am. 1.Trop. A1ed. Hyg., 71(2): pp. ]44-]52

137

Durbin AP., Karron RA, Sun W., Vaughn D.W., Reynolds M.l, Perreault lR,et aI. 200]. Attenuation and Immunogenecity in Humans of Live DengueVirus type-4 Vaccine Candidate with 30 Nucleotide Deletion in its 3'-Untranslated Region. Am. J Trop. Med. Hyg., 65 (5): p. 405-413.

Eckels KH. and Putnak R 2003. Formalin-inactivated whole virus andrecombinant subunit flavivirus vaccines. Adv Vims Res, 61: p. 395-418.

Eckels KH., Scott RM., Bancroft W.H., Brown l, Dubois D.R, Summers P.L.,et al. ]984. Selection of attenuated dengue 4 viruses by serial passage inprimary kidney cells. V. Human response to immunization with a candidatevaccine prepared in fetal rhesus lung cells. Am J Trop Med Hyg., 33 (4): p.684-9.

Edelman R, Wasserman S.S., Bodison S.A, Putnak R.l, Eckels KH., Tang D., etal. 2003. Phase I trial of 16 formulations of a tetravalent live-attenuateddengue vaccine. Am J TropMed Hyg., ;69(6 Suppl):48-60.

Espina L.M., Valero N.J., Hernandez lM., and Mosquera lA 2003. Increasedapoptosis and expresion of tumor necrosis factor a caused by infection ofcultured of human monocytes with dengue virus. Am. J Trop. Med. Hyg., 68(1): p. 48-53.

Gagnon S.J., Ennis F.A, and Rothman AL. ]999. Bystander Target Cell Lysisand Cytokine Production by Dengue Virus-Specific Human CDr CytotoxicT-Lymphocyte Clones. Journal of Virology, 73 (5): p. 3623-3629.

Gagnon S.J., Mori M., Kurane I., Green S., Vaughn D.W., Kalayanarooj S., et al.2002. Cytokine gene expression and protein production in peripheral bloodmononuclear cells of children with acute dengue virus infections. J MedVirol, 67 (1): p. 4]-6.

Green S., Vaughn D.W., Kalayanarooj S., Nimmannitya S., Suntayakorn S.,Nisalak A, et al. ] 999. Early Immune Activation in Acute Dengue Illness IsRelated to Development of Plasma Leakage and Disease Severity.The Journal £?!Infectious Diseas'es, ] 79: p. 755-762.

Green S., Kurane I., Edelman R, Tacket CO, Eckels KH., Vaughn D.W., HokeJr CH., and Ennis F.A 1993. Dengue virus-specific human CD4+ T-lymphocyte responses in a recipient of an experimental live-attenuateddengue virus type ] vaccine: bulk culture proliferation, clonal analysis, andprecursor frequency determination. J Virol., 67 (10): p. 5962-67.

Gubler D.J. 1998. Dengue and dengue hemorrhagic fever. Clinical MicrobiologyReviews, 11(3): p. 480-496.

138

Guirakhoo F., Arroyo 1., Pugachev KY., Miller c., Zhang Z.X, Weltzin R, et al.2001. Construction, Safety, and Immunogenicity in Nonhuman Primates of aChimeric Yellow Fever-Dengue Virus Tetravalent Vaccine. Journal ofVirology, 75 (16): p. 7290-7304.

Guirakhoo F., Pugachev K, Arroyo 1., Miller c., Zhang Z.X, Weltzin R, et al.2002. Viremia and immunogenicity in nonhuman primates of a tetravalentyellow fever-denbrue chimeric vaccine: genetic reconstructions, doseadjustment, and antibody responses against wild-type dengue virus isolates.Virology, 298 (1): p. 146-59.

Guirakhoo F., Pugachev K, Zhang Z., Myers G., Levenbook 1., Draper K,et aI.2004. Safety and Efficacy of Chimeric Yellow Fever-Dengue VirusTetravalent Vaccine Formulations in Nonhuman Primates. Journal qfVirology, 78 (9): p. 4761-4775

Guirakhoo F., Weltzin R, Chambers TJ., Zhang Z.X, Soike K, Ratterree M.,.Arroyo 1., et aI. 2000. Recombinant Chimeric Yellow Fever-Dengue Type2 Virus Is Immunogenic and Protective in Nonhuman Primates. Journal ofVirology, 74 (12): p. 5477-5485.

Guirakhoo F., Zhang Z., Myers G., Johnson B.W., Pugachev K, Nichols R, et aI.2004. A single amino acid substitution in the envelope protein of chimericyellow fever-dengue 1 vaccine virus reduces neurovirulence for sucklingmice and viremia/viscerotropism for monkeys. J Virol., 78 (18): p. 9998-10008.

Guzman M.G. 1998. Advances in the development of a vaccine against dengue.Acta Cient Venez., 49 Suppl 1: p. 38-45

Guzman M.G., Rodriguez R, Rodriguez R, Hennida L., Alvarez M., Lazo L., etaI. 2003. Induction of neutralizing antibodies and partial protection fron viralchallengge in Macaca Fascicularis immunized with recombinant Dengue 4virus envelope gycoprotein expressed in Pischia pastoris .Am. 1. Trap. MedHyg., 69 (2): p. 129-134.

Gwinn W., Sun W., Innis B.L., Caudill 1., and King AD. 2003. Serotype-specificTH1 responses in recipients of two doses of candidate live-attenuateddengue virus vaccines. American Journal of Tropical Medicine & Hygiene,69 (6): p. 39-47 (SuppI. S).

Hadinegoro A,RH., Soegijanto S., Wuryahadi S., dan Suroso T. 1998.Tatalaksana demam dengue/demam berdarah dengue pada anak. In SriRezeki H. Hadinegoro dan Hindra Irawan Satari: Demam berdarah dengue.Jakarta: FKUI. p. 82-84.

139

Halstead S.B. 1988. Pathogenesis of dengue: challenges to molecular biology.Science, 239 (4839): p. 476-81.

Halstead S.B. 1997. Epidemiology of dengue and dengue hemorrhagic fever. InD.1. Gubler and G. Kune: Dengue and Dengue Hemorrhagic Fever.Cambridge: University press. p. 23-44.

Halstead S.B. and Marchette N.1. 2003. Biologic properties of dengue virusesfollowing serial passage in primary dog kidney cells: Studies at theUniversity of Hawaii. American Journal of Tropical Medicine & Hygiene,69 (6): pp. 5-11 (Supp!. S).

Hanley KA., Manlucu L.R, Manipon G.G., Hanson C.T., Whitehead S.S.,Murphy B.R, et a!. 2004. Introduction of mutations into the non-structuralgenes or 3' untranslated region of an attenuated dengue virus type 4 vaccinecandidate further decreases replication in rhesus monkeys while retainingprotective immunity. Vaccine, 22 (25-26): p. 3440-8.

Hanley KA., Lee J.1., Blaney, Jr lE., Murphy B.R., and Whitehead S.S. 2002.Paired Charge-to-Alanine Mutagenesis of Dengue Virus Type 4 NS5Generates Mutants with Temperature-Sensitive, Host Range, and MouseAttenuation Phenotypes. Journal (if Virology, 76 (2): p. 525-531.

Harrison V.R, Eckels KH., Sagartz lW., and Russell P.K 1977. Virulence andimmunogenicity of a temperature-sensitive dengue-2 virus in lowerprimates. Infect Immull.,18 (1): p. 151-6.

Henke A. 2002. DNA immunization--a new chance in vaccine research? MedA1icrobiollmmunol (Berl)., 191 (3-4): p. 187-90.

Ho L.1., Wang J.1., Shaio M.F., Kao c.L., Chang D.M., Han S.W., et a!. 2001.Infection of human dendritic cells by Dengue virus causes cell maturationand cytokine production. Journal of Immunology, 166 (3): pp. 1499-1506.

Huang C.Y.H, Butrapet S., Tsuchiya KR, Bhamarapravati N., Gubler D.1., andKinney RM. 2003. Dengue 2 PDK-53 Virus as a Chimeric Carrier forTetravalent Dengue Vaccine Development. Journal of Virology, 77 (21): p.11436-11447.

Huang c.Y.H., Butrapet S., Pierro D.l, Chang G.l, Hunt A.R, BhamarapravatiN., et a!. 2000. Chimeric Dengue Type 2 (Vaccine Strain PDK-53)/DengueType 1 Virus as a Potential Candidate Dengue Type ] Virus Vaccine,Journal C?fVirology, 74 (7): p. 3020-3028.

140

Inni s B.L. 1997. Antibody responses to dengue virus infection. In D.J. Gubler andG. Kune: Dengue and Dengue Hemorrhagic Fever. Cambridge: Universitypress. p. 221-243.

Jaiswal S., Khanna N., and Swaminathan S. 2003. Replication-DefectiveAdenoviral Vaccine Vector for the Induction of Immune Responses toDenf,>ueVirus Type 2. Journal <?fVirology, 77 (23): p. 12907-12913.

Jan .LT., Chen RH., Ma S.H., Liu c.I., Tsai H.P., Wu H.C., et a1. 2000. PotentialDengue Virus-Triggered Apoptotic Pathway in Human NeuroblastomaCells: Arachidonic Acid, Superoxide Anion, and NF-KB Are SequentiallyInvolved. Journal <?fVirology, 74 (18): p. 8680-8691.

Jimenez RO. and da Fonseca B.AL. 2000.Recombinant plasmid expressing atruncated dengue-2 virus E protein without co-expression of prM proteininduces partial protection in mice. Vaccine, 19 (6): p.648-654.

Jirakanjanakit N., Khin M.M., Yoksan S., and Bhamarapravati N. 1999.Dynamics of Susceptibility and Transmissibility of the Life AttenuatedCandidate Vaccines Dengue-l PDK13, Dengue-3 PGMK30F3, and Dengue-4 PDK 48 After Oral Infection In Aedes Aegypti. Am. .J Trop. !lIed. Hyg, 61(4): p. 672-676.

Johnson B.W., Chambers T.V., Crabtree M.B., Guirakhoo F., Monath T.P., andB.R. Miller. 2004. Analysis of The Replication Kinetics of ChimeraVaxunDEN 1,2,3,4 Tetravalent Virus Mixture In Aedes aegypti by Real-TimeReverse Transcriptase-Polymerase Chain Reaction. Am. .J. Trop. Med Hyg.,70 (1): p. 89-97.

Kanesa-Thasan N., Edelman R, Tacket e.0. Wasserman S.S., Vaughn D.W.,Coster T.S., et al. 2003. Phase 1 Studies of Walter reed Army Institute ofResearch Candidate Attenuated Dengue Vaccines: Selection of Save andImmunogenic Monovalent vaccines. Am. .J Trop. !lIed. Hyg., 69(6 suppl): p.17-23.

Kankirawatana P., Chokephaibulkit K., Puthavathana P., Yoksan S.,Apintanapong S., and Pongthapisit V. 2000. Dengue infection presentingwith central nervous system manifestation. J Child Nellrol., ] 5 (8): p. 544-7

Kamen Gama Baratawidjaja. 2000. Imu17ologi Dasar. Jakarta: FKUI. p. 8.

Keelapang P., Sriburi R, Supasa S., Panyadee N., Songjaeng A, Jairungsri A, etal. 2004. Alterations of pr-M cleavage and virus export in pr-M junctionchimeric dengue viruses. Journalo/Virology, 78 (5): p. 2367-2381.

141

King C.A, Anderson R., and Marshall lS. 2002. Dengue Virus SelectivelyInduces Human Mast Cell Chemokine Production. Journal of Virology, 76(16): p. 8408-19.

King C.A, Marshall lS., Alshurafa H., and Anderson R. 2000. Release ofVasoactive Cytokines by Antibody-Enhanced Dengue Virus Infection of aHuman Mast Cell/Basophil Line. Journal of Virology, 74 (15): p. 7146-7150.

Kliks S., Nisalak A, Brandt W.E., and Burke D.S. 1988. Evidence that Maternaldengue antibodies are important in the development of dengue hemorrhagicfever in infants. American Journal C?fTropical Aledicine and Hygiene, 40:444-451.

Konishi E., Terazawa A, and Imoto 1. 2003. Simultaneous immunization withDNA and protein vaccines against Japanese encephalitis or denguesynergistically increases their own abilities to induce neutralizing antibodyin mice. Vaccine, 21 (17-18): p. 1826-1832.

Kunkel T.A 1985. Rapid and efficient site-spesific mutagenesis withoutphenotypic selection. Proc. Natl. Acad Sci. USA. 82: p. 488-492.

Kuno G. 1997. Factors influencing the transmission of dengue viruses. In DJ.Gubler and G. Kune: Dengue and Dengue Hemorrhagic Fever. Cambridge:University press. p. 61-80.

Kurane I, Innis B.L., Hoke c.H. Jr, Eckels KH., Meager A, Janus l, et al. 1995.T cell activation in vivo by dengue virus infection. J Clin Lab Immunol., 46(1): p. 35-40.

Kurane I. and Ennis F.A 1997. Immunopathogenesis of dengue virus infections.In D.l Gubler and G. Kune: Dengue and Dengue Hemorrhagic Fever.Cambridge: University press. p. 273-290.

Kurane I., Innis RL., Nimmannitya S., Nisalak A, Rothman AL., LivingstonP.G., et al. 1990. Human immune responses to dengue viruses. SoutheastAsianJ TropMed Public Health, 21 (4): p. 658-62.

Lai CJ. and Monath T.P. 2003. Chimeric tlaviviruses: novel vaccines againstdengue fever, tick-borne encephalitis, and Japanese encephalitis. Adv VirusRes., 61 :469-509.

Leitmeyer K.c., Vaughn D.W., Watts D.M., Salas R., Villalobos I., de Chacon, etal. 1999. Dengue virus structural differences that correlate withpathogenesis. J Virol., 73(6): p. 4738-47.

142

Leonard E Munstermann. 1995.)1t.112~/.kl~b~1&~cift:,~tQ~t;!lC _~Q_~!~a.~.gX12li:11_~'g}lltLb1Jll1,05 -0 5-1 004.

Libraty D.H., Pichyangkul S., Ajariyakhajorn c., Endy T.P., and Ennis F.A. 2001.Human Dendritic Cells Are Activated by Dengue Virus Infection:Enhancement by Gamma Interferon and Implications for DiseasePathogenesis. Journal of Virology, 75 (8): p. 3501-3508.

Libraty D.H., Endy T.P., Houng H.S.H, Green S., Kalayanarooj S., SuntayakornS., et al. 2002. Differing Influences of Virus Burden and Immune Activationon Disease Severity in Secondary Dengue-3 Virus Infections. The Journal ofInfectious Diseases, 185: p. 1213-1221.

Lin YW., Wang K.1., Lei H.Y, Lin YS., Yeh T.M., Liu H.S.,et al. 2002. VirusReplication and Cytokine Production in Dengue Virus-Infected Human BLymphocytes. Journal of Vim logy, 76 (23): p. 12242-12249.

Lindenbach B.D. and Rice C.M. 1999. Genetic interaction of Flavivirusnonstructural protein NS 1 and NS4 A as a determinant of replicase function.Journal of Virology, 73 (6): p. 4611-4621.

Littaua R., Kurane I., and Ennis F.A. 1990. Human IgG receptor II mediatesantibody-dependent enhancement of dengue virus infection. The Journal C?!Immunology, 144: p. 3183-3186.

Livingston P.G., Kurane I., Lai C.1., Bray M., and Ennis F.A. 1994. Recognitionof envelope protein by dengue virus serotype-specific human CD4+ CD8-cytotoxic T-cell clones. J Vim!., 68 (5): p. 3283-8.

Loke H., Bethell D.B., Phuong e.X.T., Dung M., Schneider 1., White N.1.,et al.2001. Strong HLA Class I - Restricted T Cell Responses in DengueHemorrhagic Fever: A Double-Edged Sword? The Journal C?fb!fectiollsDiseases, 184: p. 1369-1373.

Lopez Antunano F.1. and Mota 1. 2000. Development of immunizing agentsagainst dengue. Rev Panam Salud Publica., 7 (5): p. 285-92.

Lu Y, Raviprakash K., Leao I.e., Chikhlikar P.R., Ewing D., Anwar A., et al.2003. Dengue 2 PreM-E/LAMP chimera targeted to the MHC class IIcompartment elicits long-lasting neutralizing antibodies. Vaccine, 21 (17-18): p. 2178-2189.

Mady B.1., Erbe D.V., Kurane I., Fanger M.W., and Ennis F.A. 1991. Antibodydepedent enhancement of dengue virus infection mediated by bispesificantibodies against cell surface molecules other than Fcy receptors. TheJournal of Immunology, 147: p. 3139-3144.

143

Mangada M.M, Endy T.P., Nisalak A, Chunsuttiwat S., Vaughn D.W., LibratyD.H, et al 2002. Dengue spesific E cell responses in pheripheral bloodmononuclear cell obtained prior to secondary dengue virus infections in Thaischool childreen. The Journal qf Infectious Diseases, 185: p. 1697-1703.

Mangada M.M., Ennis F.A, and Rothman AL. 2003. Quantitation of denguevirus specific CD4+ T cells by intracellular cytokine staining. Journal qfImmunological Methods, 284 (1-2): p. 89-97.

Marianneau P., Cardona A, Edelman L., Deubel V., and Despres P. 1997. Denguevirus replication in human hepatoma cells activates NF-kappaB which inturn induces apoptotic cell death. J. Virol., 71 (4): p. 3244-3249.

Markoff L., Pang XW., Houng HS., Falgout B., Olsen R., Jones E., et al. 2002.Derivation and Characterization of a Dengue Type 1 Host Range-RestrictedMutant Virus That Is Attenuated and Highly Immunogenic in Monkeys.Journal of Virology, 76 (7): p. 3318-3328.

Martinez-Barragim J. and del Angel R.M. 2001. Identification of a PutativeCoreceptor on Vero Cells That Participates in Dengue 4 Virus Infection.Journal of Virology, 75 (17): p. 7818-27.

Matusan AE., Pryor M.J., Davidson AD., and Wright PJ. 2001. Mutagenesis ofthe Dengue Virus Type 2 NS3 Protein within and outside Helicase Motifs:Effects on Enzyme Activity and Virus Replication. Journal qf Virology, 75(20): p. 9633-43.

McBride WJ.H and Bielefeldt-Ohmann H. 2000. Dengue viral infections;pathogenesis and epidemiology. Microbes and Infection, 2: p. 1041-1050.

Men R., Bray M., Clark D., Chanock R.M., and Lai c.J. 1996. Dengue type 4virus mutants containing deletions in the 3' noncoding region of the RNAgenome: analysis of growth restriction in cell culture and altered viremiapattern and immunogenicity in rhesus monkeys. J. Virol., 70 (6): p. 3930-37.

Modis Y, Ogata S., Clements D., and Harrison S.c. 2003. A ligand-bindingpocket in the dengue virus envelope glycoprotein. PNAS, 100 (12): p. 6986-91.

Modis Y, Ogata S., Clements D., and Harrison S.c. 2004. Structure of the denguevirus envelope protein after membrane fusion. Nature, 427: p. 313 - 319.

Moreno-Altamirano M.M, Sanchez-Garcia FJ., and Munoz M.L. 2002. Non Fcreceptor mediated infection of human macrophages by dengue virusserotype 2. Journal qfGeneral Virology, 82: p.1123-1130.

144

Muhareva R. 2004. Belajar dari wabah virus dengue.http://www. k01)lpassonJ/kQmQas.:~1i!.kL0493/l2/om!!j.htn.1,13-03-2004.

Mune M., Rodriguez R., Ramirez R., Soto Y., Sierra B., Rodriguez Roche R.,et al.2003. Carboxy-terminally truncated Dengue 4 virus envelope glycoproteinexpressed in Pichi a pastoris induced neutralizing antibodies and resistance toDengue 4 virus challenge in mice. Arch Virol.,148 (11): p. 2267-73.

PAHO. Facing the dengue threat: a blueprint for action.http://ww\V.paho.orgiEnglish/HCP/HL'TlYB D/ncw-gcneration-bp. pdf 27-03-2004.

Pang X.W., Zhang M.J, and Dayton AI. 2001. Development of dengue virusreplicons expressing HIV-l gp120 and other heterologous genes: a potentialfuture tool for dual vaccination against dengue virus and HIV. BMCMicrobiol., 1 (1): 28.

Pang X.W., Zhang M.1., and Dayton AI. 2001. Development of Dengue virustype 2 replicons capable of prolonged expression in host cells. BMCMicrobiol., ] (1): p. 18.

Polo S., Ketner G., Levis R., and Falgout B. ]997. Infectious RNA transcriptsITom full-length Dengue virus type 2 cDNA clones made in yeast. J Viro!.,71 (7): p. 5366-74.

Pugachev KY., Guirakhoo F., Ocran S.W., Mitchell F., Parsons M., Penal e., etal. 2004. High Fidelity of Yellow Fever Virus RNA Polymerase. Journal ofVirology, 78 (2): p. 1032-1038.

Pugachev KV., Guirakhoo F., Trent D.W., Monath T.P. 2003. Traditional andnovel approaches to tlavivirus vaccines. Inl J Parasilol., 33 (5-6): p. 567-82.

Putnak R., Fuller 1., Vanderzanden L., Innis B.L., and Vaughn D.W. 2003.Vaccination of Rhesus Macaques against Dengue-2 Virus with A PlasmidDNA Vasccine Encoding The Viral Pre-Membrane and Envelopes Genes.Am. J Trop. Med Hyg., 68 (4): p. 469-476.

Rabablert 1., Dharakul 1., Yoksan S., Bhamarapravati N. 2000. Dengue virusspecific T cell responses to live attenuated monovalent dengue-2 andtetravalent dengue vaccines. Asian Pac J Allergy Immuno!., 18 (4): p. 227-35.

Raviprakash K, Ewing D., Simmons M., Porter KR., Jones 1.R., Hayes e.G., eta1. 2003. Needle-free Biojector injection of a dengue virus type] DNAvaccine with human immunostimulatory sequences and the GM-CSF gene

145

increases immunogenicity and protection from VIruS challenge In Aotusmonkeys. Virology, 315 (2): p. 345-52.

Rey F.A 2003. Dengue virus envelope glycoprotein structure: New insight intoits interactions during viral entry. PNAS, 100 (12): p. 6899-6901.

Rico-Hesse R 2003. Microevolution and virulence of dengue viruses. Adv VirusRes., 59: p. 315-41.

Roehrig 1.1. 1997. Immunochemistry of dengue viruses. In DJ. Gubler and G.Kune: Dengue and Dengue Hemorrhagic Fever. Cambridge: Universitypress. p. 199-219.

Rothman AL. 1997. Viral pathogenesis of dengue infection. In DJ. Gubler andG. Kune: Dengue and Dengue Hemorrhagic Fever. Cambridge: Universitypress. p. 245-271.

Rothman AL. 2004. Dengue: defining protective versus pathologic immunity. JClin Invest. 113 (7): p. 946-951.

Rothman AL., Kanesa-thasan N., West K., Janus 1., Saluzzo 1.F., and Ennis F.A2001. Induction of T lymphocyte responses to dengue virus by a candidatetetravalent live attenuated dengue virus vaccine. Vaccine, 19 (32): p. 4694-9.

Rothman AL., Kurane I., and Ennis F.A 1996. Multiple specificities in themurine CD4+ and CD8+ T-cell response to dengue virus. J Viral.,70 (10): p.6540-6.

Rothman AL., Kurane I., Lai CJ., Bray M., Falgout B., Men R and Ennis F.A1993. Dengue virus protein recognition by virus-specific murine CD8+cytotoxic T lymphocytes. Journal of virology, 67 (2): p. 801-806

Sabchaeron A, Lang 1., Chathavanich P., Yoksan S., Forrat R, Attanath P., et al.Safety and Immunogenecity of Tetravalent Life Attenuated DengueVaccines In Thai Adult Volunteers: Role of Serotype Concetration, Ratio,and Multiple Doses. Am. J Trop. Med Hyg. 66 (3): p. 264-272.

Sabchareon A, Lang 1., Chanthavanich P., Yoksan S., Forrat R, Attanath P., et al.2004. Safety and immunogenicity ofa three dose regimen of two tetravalentlive-attenuated dengue vaccines in five- to twelve-year-old Thai children.Pediatr Infect Dis J, 23 (2): p. 99-109.

Salas-Benito 1.S. and del Angel RM. 1997. Identification of two surface proteinsfrom C6/36 cells that bind Dengue type 4 virus. J Virol., 71 (10): p. 7246-52.

146

Sardelis M.R., Edelman R., Klein T.A., Innis B.L., Putnak 1.R., Jones 1.W., et al.2000. Limited Potensial For Transmision Of Live Dengue Virus VaccineCandidates By Aedes Aegypti and Aedes Albopictus. Am. J Trap. Hyg., 62(6): p 698-704.

Schmaljohn A.L and McClain D. 2001. Alphaviruses (Togaviridae) andFlaviviruses (Flaviviridae). ht!1L2g_sb~Jltl]]h&d:!J/m !~LQ.boQ}:J.'.0JO~4.htn}, 05-05-1004.

Shresta S., Kyle 1.L., Snider H.M., Basavapatna M., Beatty P.R., and Harris E.2004. Interferon-Dependent Immunity Is Essential for Resistance toPrimary Dengue Virus Infection in Mice, Whereas T- and B-Cell-DependentImmunity Are Less Critical. Journal qfJ;7rology, 78 (6): p. 2701-2710.

Simon S., Saputra E.J., dan Nirmalasari O. 2004. Dengue hemorrhagic fever: anIndonesian perspective. Majalah Kedokleran Alma Jaya, 3 (1): p. 37-49

Soedarmo S.P. 1998. Masalah demam berdarah dengue di Indonesia. In SriRezeki H. Hadinegoro dan Hindra Irawan Satari: Demam berdarah dengue.Jakarta: FKUl p.1-31.

Soegijanto S. 2004. Aspek imunologi penyakit demam berdarah dengue. InSoegeng Soegijanto: Demam berdarah dengue: tinjauan dan temuan barn diera 2003. Surabaya: Airlangga University Press. p. 11-25.

Soegijanto S., Rantam F.A, Soetjipto, Sudiana K., dan Priyatna Y. 2004.Mencermati vaksin dengue rekombinan protein E sebagai calom andalanvaksin di masa depan. In Soegeng Soegijanto: Demam berdarah dengue:tinjauan don temuan barn di era 2003. Surabaya: Airlangga UniversityPress. p.79-90.

Sun W., Edelman R., Kanesa-Thasan N., Eckels K.H., Putnak 1.R., King AD., etal. 2003 Vaccination of human volunteers with monovalent and tetravalentlive-attenuated dengue vaccine candidates. Am J Trop A1ed Hyg., 69 (6Suppl): p. 24-31.

Tacio RD. 2003. Dengue vaccine developed.http://v..:ww.mani1atimes.!L~i.!Jj1JjQ!1:;ttL~.OQ:i@1.1 Q/Q91Ji t~/ lill! in] i [;11tm J 09-08-

2004.

Tassaneetrithep B., Burgess T.R, Granelli-Piperno A, Trumpfbeller C, Finke 1.,Sun W., et al. 2004. DC-SIGN (CD209) Mediates Dengue Virus Infection ofHuman Dendritic Cells. 171eJournal qf Experimental Medicine, 197 (7): p.823-829.

147

Tim Penanggulangan DBD Departemen Kesehatan RI. 2004. Kasus DemamBerdarab Dengue (DBD) di Indonesia.hUQ :/;~~l.DLd.~.j)1:~s.g.Q.jdL~ioY0.1.lQ.i:Lci<>L1:tuh~!il1°.(':WDlrD()/o2Q[:0k9l>:h'tIrr~'2_2 OQ

:L129J,01-10-2004

Trent D.W., Kinney RM., and Huang C.YH. 1997. Recombinant dengue virusvaccine. In D.l Gubler and G. Kune: Dengue and Dengue HemorrhagicFever. Cambridge: University press. p. 61-80.

Troyer lM., Hanley KA, Whitehead S.S., Strickman D., Karron RA, DurbinAP., and Murphy B.R 2001. A live attenuated recombinant dengue-4 virusvaccine candidate with restricted capacity for dissemination in mosquitoesand lack of transmission from vaccinees to mosquitoes. Am J Trop MedHyg. 65 (5): p. 414-9.

Valdes K, Alvarez M., Pupo M., Vazquez S., Rodriguez R, and Guzman M.G.2000. Human Dengue Antibodies against Structural and NonstructuralProteins. Clin Diagn Lab Immunol, 7 (5): p. 856-857

Van der Most RG., Murali-Krishna K, Ahmed R, and Strauss lH. 2000.Chimeric Yellow Fever/Dengue Virus as a Candidate Dengue Vaccine:Quantitation of the Dengue Virus-Specific CD8 T-Cell Response. Journal qfVirology, 74 (17): p. 8094-8101.

Vaughn D.W., Green S., Kalayanarooj S., Innis B.L., Nimmannitya S.,Suntayakorn S., et at. 1997. Dengue in the early febrile phase: viremia andantibody responses. J bifect Dis, 176 (2): p. 322-30.

Vaughn D.W., Green S., Kalayanarooj S., Innis B.L., Nimmannitya S.,Suntayakorn S.,et al. 2000. Dengue viremia titer, antibody response pattern,and virus serotype correlate with disease severity. J b?fect Dis., 181 (1): p. 2-9.

Wang S., He R, and Anderson R 1999. PrM- and Cell-Binding Domains of theDengue Virus E Protein. Journal (if Virology, 73 (3): p. 2547-2551.

Warke RY., Xhaja K, Martin Kl, Fournier M.F., Shaw S.K, Brizuela N., et al.2003. Dengue Virus Induces Novel Changes in Gene Expression of HumanUmbilical Vein Endothelial Cells. Journal of Virology, 77 (21): p. 11822-11832.

Watanaveeradej Y., Endy T.P., Samakoses R. Kerdpanich A, Simasathien S.,Polpresert N., et al. 2003. Transplacentally Transferres Maternal-InfantAntibodies to Dengue Virus. Am. J. Trop. Med. Hyg., 69(2): p. 123-128.

148

Watts D.M., Porter KR., Putvatana P., Vasquez B., Calampa e., Hayes e.G., etal. 1999. Failure of secondary infection with American genotype dengue 2 tocause dengue haemorrhagic. Lancet, 354 (9188): p. 1431-4.

Whitehead S.S., Falgout B., Hanley KA., Blaney, If. lE., Markoff L., andMurphy B.R. 2003. A Live, Attenuated Dengue Virus Type 1 VaccineCandidate with a 30-Nucleotide Deletion in the 3' Untranslated Region IsHighly Attenuated and Immunogenic in Monkeys. Journal of Virology, 77(2): p. 1653-1657.

Whitehead S.S., Hanley KA., Blaney lE. Jr, Gilmore L.E., Elkins W.R., andMurphy B.R. 2003. Substitution of the structural genes of dengue virus type4 with those of type 2 results in chimeric vaccine candidates which areattenuated for mosquitoes, mice, and rhesus monkeys. Vaccine. 21(27-30):p.4307-16.

WHO, Dengue Vaccine Development, Starns, challenges, and WHO priorities,http://\vww.cidfa2004 .sld.cu/confcrcnci a/vcr .php?id=91, 06-05-2004.

WHO, http://www.wbo.int/csridon/2004 04 OS/cn!, 05-05-2004.

WorId Health Organization, 1997, Dengue haemorrhagic fever: diagnosis,treatment, prevention and control. 2nd edition.http://www.\vho.int/cmc/discases/ebola/Den\.!ucpubJicatio11/00 l-ll.pdf . 27-4-2004.

World Health Organization, 1997,httP~i/\\:vv\v.\\JlQ.intl.m~dja~,-GJ1tr~it}J.~tsl~.s;l~d~U7/cnL , 27 -4-2004.

Wu S.F., Liao e.L., Lin YL., Yeh e.T., Chen L.K, Huang YF., et al. 2003.Evaluation of protective efficacy and immune mechanisms of using a non-structural protein NS 1 in DNA vaccine against dengue 2 virus in mice.Vaccine,21 (25-26): p. 3919-29.